BG
ABUS icon

BlackRock Group’s Arbutus Biopharma ABUS Stock Holding History

BlackRock Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-113,900
Closed -$2.41M – 2869
2014
Q3 		$2.41M Hold
113,900
– – ﹤0.01% 1347
2014
Q2 		$1.49M Hold
113,900
– – ﹤0.01% 1614
2014
Q1 		$2.45M Buy
+113,900
New +$2.05M ﹤0.01% 1438

Other funds holding ABUS

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $5.28B AUM 14.42% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BlackRock Group's ABUS Position: Q4 2014 in Review

BlackRock Group sold out of Arbutus Biopharma (ABUS) in Q4 2014, closing a stake of 113,900 shares — an estimated $2.41M sold.

BlackRock Group first reported a position in ABUS in Q1 2014 and held it in 3 quarters. The position peaked at $2.45M in Q1 2014. 49 funds tracked by Wall St. Rank hold ABUS as of Q4 2014.

  • BlackRock Group reported no remaining Arbutus Biopharma position as of Q4 2014 after selling out during the quarter.
  • BlackRock Group sold 113,900 Arbutus Biopharma shares in Q4 2014, an estimated $2.41M.
  • BlackRock Group first reported a position in Arbutus Biopharma in Q1 2014 and held it in 3 quarters.
  • BlackRock Group's Arbutus Biopharma position peaked at $2.45M in Q1 2014.
  • 49 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2014.

Based on BlackRock Group's 13F filing for Q4 2014, filed 9 Feb 2015.